CHRETO - A paradigm shift in mAb purification

PROTEIN A CAPTURE OFIMMUNOGLOBULINS IN SOLUTION: SKIP THE PROTEIN A COLUMN Our vision is that the CHRETO Technology™ will - radically improve the process efficiency of downstream processing of large biomolecules - increase yields in existing production, especially IVIG - bring more monoclonal antibody (mAb’s) candidates to testing. - speed up initial clinical phases - result in better and more efficient treatment of diseases. We believe that CHRETO’s Protein Purification Technology will bring a true revolution to bio-manufacturing, which has been sought by the industry for decennia. CHRETO was founded in 2010, as a spin out of Novozymes, by the inventor Jan Kyhse-Andersen and Torben Jørgensen to develop and commercialize a novel protein purification technology for bio-manufacturing. The company acquired in 2014 the rights to the original IP related to protein purification technology from Novozymes, DK. A prototype of the technology has been developed and thoroughly tested by industry experts and a leading biopharmaceutical company in Europe during 2014/16. The Technology is expected to be introduced late 2020 How does the CHRETO Technology for mAb purification: The purification process consists of three steps: catch, clean and collect. Catch. The DAP molecule reacts in solution with the feed stream containing the target molecule(s) e.g., an antibody. Clean. Impurities including HCP (host cell proteins) and DNA are removed followed by dissociation of the DAP-antibody complex and capture of DAP to a biotin support. Collect. The purified antibody is collected and the membrane cartridge is discharged. Benefits: - Process improvements on 30% - The cost for manufacturing material used in clinical trials is likely to be reduced by a factor of 20. INTERESTED? Contact us for more information: info@chreto.com